INTRODUCTION {#sec1-1}
============

The metabolic syndrome in adults has been defined as a complex of inter-related risk factors for cardiovascular disease and type 2 diabetes mellitus (T2DM).\[[@ref1]\] The worldwide prevalence of metabolic syndrome ranges from \<10% to as high as 48% depending on the population studied.\[[@ref2]\] The prevalence of metabolic syndrome in the Kingdom of Saudi Arabia is decreasing, while dyslipidemia remains high, affecting almost 90% of middle-aged Saudi males.\[[@ref3]\] Among metabolic syndrome components, low high-density lipoprotein (HDL)-hypertriglyceridemia and cholesterol were the most prevalent in one study, affecting 88.6% and 34% of the subjects, respectively.\[[@ref3]\]

The National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) has defined metabolic syndrome by the presence of at least three of the following components: abdominal obesity (waist circumference \>40 inches in men and \>34 inches in women); hypertriglyceridemia (triglyceride level ≥150 mg/dL \[1.69 mmol/L\]); low HDL-cholesterol level (\<40 mg/dL \[1.04 mmol/L\] in men and \<50 mg/dL \[1.29 mmol/L\] in women); high blood pressure (≥130/85 mmHg) and high fasting glucose (≥110 mg/dL \[6.1 mmol/L\]).\[[@ref4]\] Here, we report on a patient who met all five components identified by NCEP/ATP III for the definition of metabolic syndrome and who presented with abdominal pain, a complaint not usually suggestive of metabolic syndrome as a comorbidity or cause.

CASE REPORT {#sec1-2}
===========

A 26-year-old Saudi male with no previous significant medical history presented to the emergency department with a 1-week history of abdominal pain. It was graded as 7 out of 10 and unrelated to food intake. There was no associated history of vomiting or altered bowel habits. There was history of polyuria and polydipsia, but no history of polyphagia, no noticed weight changes and no history to suggest thyroid dysfunction. His family history revealed that his mother suffered from T2DM and both his parents suffered from hypertension without any significant cardiovascular events. His physical examination revealed the following: height, 169 cm; weight, 88.8 kg; body mass index, 31 kg/m^2^; waist circumference, 42.8 inches; hip circumference, 43.5 inches and neck circumference, 17 inches. The rest of his systemic examination was unremarkable, including a normal fundus examination and normal neurological testing. Investigations revealed milky blood \[[Figure 1](#F1){ref-type="fig"}\]. He had a hemoglobin value of 15.5 g/dL; total leukocyte count of 6.7 k/uL; platelet count of 263 k/uL; random plasma glucose level, 698 mg/dL; blood urea, 8.0 mg/dL and serum creatinine1.0 mg/dL. The lipid profile was abnormal with the following values: serum cholesterol, 334 mg/dL; serum triglyceride, 3872 mg/dL; serum HDL, 27 mg/dL and serum low-density lipoprotein, 52 mg/dL. Amylase and lipase were normal as was the liver chemistry. Routine urine examination revealed yellow-colored urine, not turbid and neutral (pH of 6.0) with trace proteinuria. Glycated hemoglobin level (hemoglobin A1C) was 12.1%. Radiological investigations were normal. The patient was given adequate hydration, analgesics, insulin and the lipid-lowering agent fenofibrate, after which he was discharged and advised regarding follow-up care. This patient met the NCEP/ATP III-defined criteria for metabolic syndrome. He also fit the diagnostic criteria for T2DM. Despite his very high triglyceride level, he showed no evidence of pancreatitis or cutaneous involvement that is characteristic of dyslipidemia.

![Blood sample with milky appearance (lipemia)](SJMMS-5-172-g001){#F1}

DISCUSSION {#sec1-3}
==========

Various criteria have been used to define metabolic syndrome; we describe the widely accepted NCEP/ATP III consensus definition.\[[@ref4]\] Early detection and management play a key role in the management of metabolic syndrome to avoid future complications, given the increasing burden of morbidity and mortality resulting from components of the disease.\[[@ref5]\] The American College of Cardiology/American Heart Association Cholesterol Guidelines for arteriosclerotic cardiovascular disease risk reduction in adults highlight the importance of dyslipidemia management in patients with T2DM.\[[@ref6]\] Lipid-lowering agent fen fibrate is considered when the triglyceride level is \>500 mg/dL,\[[@ref6]\] it affects the actions of enzymes in the liver, enabling the liver to absorb more fatty acids, thus reducing production of triglycerides, increasing the production of HDL.\[[@ref6]\]

Weight reduction and glycemic control are the important parts of metabolic syndrome management; a realistic goal is to reduce the body weight by 7--10%.\[[@ref7]\] Weight reduction has been shown to improve glycemic control by increasing insulin sensitivity and glucose uptake and diminishing hepatic glucose output.\[[@ref8]\] The American Diabetes Association and Joint National Committee (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) recommend a target blood pressure goal of \<130/80 mmHg for patients with T2DM.\[[@ref9]\] Angiotensin-converting enzyme inhibitors are the preferred therapeutic agents because they can prevent microvascular and macrovascular complications.\[[@ref10]\]

CONCLUSION {#sec1-4}
==========

Metabolic syndrome is common, and clinicians need to be vigilant for unexpected presentations in patients at risk. Obesity and a lack of physical exercise are closely related to metabolic syndrome. This case report highlights the methods that should be adopted in the management of patients with metabolic syndrome.
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